The FDA's complete response letter is often seen as a setback as it indicates that the agency has completed its review of a new drug application and has questions that prevent it from approving the drug. This news is directly related to Amneal Pharmaceuticals and is likely to negatively impact investor sentiment, leading to a decrease in the company's stock price.